HDA UK Media And Political Bulletin – 6 February 2017

Media Summary

Medicines evaluation not keeping pace with scientific progress, says ABPI

ABPI, 3 January 2017

In response a new breast cancer medicine’s being ruled too expensive to justify use on the NHS, The Association of the British Pharmaceutical Industry has criticised the way NICE currently evaluates treatments. The ABPI’s Commercial Director, Dr Richard Torbett, said that the ‘worst possible outcome for a pharmaceutical company is to spend time and money discovering and developing a new medicine and for it not to reach a patient. We hope that in this case the company and NICE can resolve the issue as quickly as possible’.

‘£200m boost’ for pharma and aerospace

The Times, 6 January 2017

A hard Brexit could boost the pharmaceutical and aerospace sectors by more than £200 million. Profit margins could increase as under World Trade Organisation rules they will be protected from tariffs. As two of Britain’s most thriving export sectors, both industries had been concerned about the impact of Brexit. A new study by Bain & Co., however, suggests that they may in fact benefit from Britain’s departure from the EU.

Parliamentary Coverage

There is no Parliamentary Coverage.

Full Coverage

Medicines evaluation not keeping pace with scientific progress, says ABPI

ABPI, 3 January 2017

Following the news that a new breast cancer medicine -Palbociclib – from Pfizer has been ruled too expensive to justify its use on the NHS by the National Institute for Health and Care Excellence (NICE), ABPI’s Commercial Director, Dr Richard Torbett said it was time to review the way in which modern cancer medicines are appraised as cost-effective.

“Today’s ruling is another is blow for breast cancer patients and further reiterates why we need to change the way in which modern cancer medicines are evaluated. Scientific breakthroughs mean that more and more new cancer medicines are given in combination with existing treatments resulting in more patients living longer and living healthier.

Unfortunately the way NICE evaluates these treatments is not keeping pace with this progress. Increasingly cancer treatment combinations are viewed as not being cost effective before the price of the new medicine is even taken into account and we end up with the bizarre situation where the medicine wouldn’t be approved even if we paid patients to take it.

​The worst possible outcome for a pharmaceutical company is to spend time and money discovering and developing a new medicine and for it not to reach a patient. We hope that in this case the company and NICE can resolve the issue as quickly as possible.”

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?